The latest financial statement is for the year ending 2025-12-28.
| Cash Flow | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 |
|---|---|---|---|---|
| Net loss | -156,607 | -222,534 | -214,132 | -51,622 |
| Depreciation, accretion and amortization | 35,112 | 44,961 | 34,009 | 7,425 |
| Amortization of right-of-use assets | - | - | - | 547 |
| Stock-based compensation | 49,367 | 58,837 | 69,452 | 30,367 |
| Change in fair value of common stock warrants | -21,832 | -12,244 | -6,180 | -75,180 |
| Impairment of equipment | - | - | 4,411 | 4,921 |
| Issuance of convertible preferred stock warrants (non-cash) | - | - | - | 0 |
| Gain on bargain purchase of assets | 4,761 | - | - | - |
| Change in fair value of convertible promissory notes | - | - | - | 0 |
| Impairment and loss on disposal of long-lived assets | 0 | 38,258 | - | - |
| Loss (gain) on early debt extinguishment | - | - | - | 0 |
| Interest expense (non-cash) | 9,222 | - | - | 0 |
| Others | -711 | -448 | -703 | - |
| Accounts and notes receivables | 3,935 | 2,465 | 370 | 170 |
| Inventory | 5,510 | -1,073 | -4,509 | 634 |
| Prepaid expenses and other assets | 85 | 2,211 | 626 | 2,828 |
| Deferred contract costs | - | - | - | -3,754 |
| Accounts payable | 4,690 | -7,970 | 6,096 | 2,272 |
| Accrued expenses and compensation | 1,554 | 3,016 | 1,977 | 2,547 |
| Deferred revenue | -1,987 | -3,058 | -3,860 | -4,091 |
| Deferred tax liability | -1,305 | -2,697 | -813 | - |
| Other liabilities | 75 | -2,047 | 188 | -48 |
| Net cash used in operating activities | -95,291 | -108,633 | -104,636 | -82,740 |
| Purchase of property and equipment | 18,223 | 76,188 | 61,795 | 36,212 |
| Payment for business acquisition | 10,000 | - | - | - |
| Routejade acquisition, net of cash and restricted cash acquired | 0 | 0 | 9,968 | - |
| Purchases of investments | 584,938 | 31,812 | 138,343 | - |
| Maturities of investments | 74,892 | 106,621 | 67,150 | - |
| Net cash used in investing activities | -538,269 | -1,379 | -142,956 | -36,212 |
| Proceeds from business combination and pipe financing | - | - | 0 | 0 |
| Payments of transaction costs related to common stock issuance | - | - | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 107,192 | - | - |
| Proceeds from exercise of common stock warrants | 232,106 | 0 | 0 | 52,828 |
| Payments of issuance costs related to common stock and warrant dividends | 7,077 | - | - | - |
| Proceeds from issuance of convertible preferred stock, net | - | - | - | 0 |
| Proceeds from issuance of convertible senior notes and loan borrowing | 360,000 | - | - | - |
| Proceeds from issuance of convertible senior notes and loans | - | 4,572 | 172,500 | 0 |
| Payments of debt issuance costs | 11,175 | 0 | 5,917 | 0 |
| Purchase of capped calls | 45,288 | 0 | 17,250 | - |
| Repayment of debt | -919 | 209 | 69 | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,323 | 1,506 | 2,350 | 1,900 |
| Proceeds from exercise of convertible preferred stock warrants | - | - | - | 0 |
| Payroll tax payments for shares withheld upon vesting of rsus | 6,543 | 7,079 | 3,931 | 587 |
| Proceeds from the exercise of stock options and issuance of common stock under atm, net of issuance costs | 3,342 | 44,771 | 11,928 | 2,379 |
| Repurchase of unvested restricted common stock | 0 | - | - | - |
| Repurchase of common stock | 58,385 | 4 | 26 | 10 |
| Net cash provided by financing activities | 467,384 | 150,749 | 159,585 | 56,510 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -536 | -1,169 | 154 | - |
| Change in cash, cash equivalents, and restricted cash | -166,712 | 39,568 | -87,853 | -62,442 |
| Cash and cash equivalents and restricted cash, beginning of period | 274,691 | 235,123 | 322,976 | 385,418 |
| Cash and cash equivalents and restricted cash, end of period | 107,979 | 274,691 | 235,123 | 322,976 |
Enovix Corp (ENVX)
Enovix Corp (ENVX)